Fundraising Fox

Cellevate

Long Beach, US · Founded 2025 · Delaware corporation · 5 known investors

cellevate.com ↗

Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.

Advanced ManufacturingBiotechDeep TechMedical DevicesNew Materials

Founders & leadership

Cellevate was founded in 2025 by Maximilian Ottosson.

MOMaximilian Ottosson
Maximilian OttossoninFounder
CM
Clint MonfortNamed on SEC filing

Investors · 5

Industrifonden✓ verifiedStockholm · $1.1M – $4.3M
European Investment Bank✓ verifiedLuxembourg
Onsight Ventures✓ verifiedInnsbruck · $216K – $2.2M
EICreportedOrinda
European Innovation Council Fundreported

Reported raises · per SEC filings

Form D private placements

$25K disclosed across 1 of 2 rounds · 2025–2026

▶$25KraisedJun 2025 · 1 investors · Other
Rule 506(b)
Officers, directors & promoters on the filing
  • Clint MonfortExecutive Officer, Director, Promoter
Offering amount
$2M
Amount sold
$25K
First sale
May 2025
Incorporated
Corporation, Delaware, 2025
Federal exemptions
04, 06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Cellares3 shared keywordsCellares develops automated manufacturing systems and technology platforms to accelerate the production and commercialization of cell therapies. The company serves biopharmaceutical manufacturers and cell therapy developers worldwide.
Celldex Therapeutics, Inc.3 shared keywordsCelldex is a biotechnology company developing therapeutics across therapeutic areas including immunology and inflammation. The page shown is a board director biography rather than a company overview.
Cellphire3 shared keywordsCellphire Therapeutics develops platelet-based and freeze-dried cellular therapeutics for transfusion medicine, focused on controlling hemorrhage. Through its veterinary subsidiary BodeVet, it also markets freeze-dried platelet products for companion and exotic animals.

Companies competing with Cellevate for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Cellevate Raises €2M to Scale Nanofiber Technology for Biopharma Manufacturing - StartupMafia - News from startup industrystartupmafia.eu · Apr 2026Cellevate raises 3.2 MEUR - Nordic Angelsnordicangels.com · Sep 2024Cellevate raises $3.6M to enter into global commercializationpharmaceuticalprocessingworld.com · Sep 2024Cellevate raises 39 million SEK - BioProcess Insiderbioprocessintl.com · Oct 2023Cellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launch - Medicon Villagemediconvillage.se · Oct 2023Cellevate | Cellevate raises 39 million SEK in Seed Financing to accelerate their global commercial launchcellevate.com · Oct 2023

Frequently asked questions

What does Cellevate do?
Cellevate develops Cellevat3d nanofiber-based microcarriers and cell culture systems for upstream bioprocessing, used in viral vector, viral vaccine, and stem cell production by gene therapy and biopharmaceutical organizations. Founded as a spinout from NanoLund and Prof. Lars Montelius's group, the company focuses on commercializing nanofiber cell culture technology.
Who founded Cellevate?
Cellevate was founded by Maximilian Ottosson in 2025.
Who are Cellevate's investors?
Cellevate's investors include Industrifonden, European Investment Bank, Onsight Ventures, EIC, European Innovation Council Fund.
How much funding has Cellevate raised?
Cellevate has disclosed $25K raised across 1 of its 2 known rounds.
Where is Cellevate headquartered?
Cellevate is headquartered in Long Beach, US.